On the night of August 18, Hengrui Medicine released its performance report for the first half of 2023, which shows that Hengrui Medicine achieved an operating income of 11.168 billion yuan, a year-on-year increase of 9.19%; net profit attributable to shareholders of listed companies was 2.308 billion yuan, a year-on-year increase of 8.91%; net profit attributable to shareholders of listed companies after excluding non-recurring gains and losses was 2.243 billion yuan, a year-on-year increase of 11.68%. After the company's revenue and net profit returned to positive growth in the first quarter of this year, the company's performance has maintained a steady upward trend. External analysts believe that this means that Hengrui's performance has returned to the upward channel.

Faced with the complex and ever-changing internal and external environment, Hengrui Medicine remains determined, continues to steadily promote technological innovation and internationalization strategies, and continues accelerating innovative research and development. In the first half of 2023, the cumulative R&D investment is 3.058 billion yuan, of which 2.331 billion is expended R&D investment. Meanwhile, Hengrui Medicine continues to improve its operation and management mechanism to promote quality and efficiency improvements, and the sales rate has further dropped to 32.9% from 34.5% in 2022.

From TouTiao.com

August 18th, 2023